General description
ZooMAb® antibodies represent an entirely new generation of recombinant monoclonal antibodies. Each ZooMAb® antibody is manufactured using our proprietary recombinant expression system, purified to homogeneity, and precisely dispensed to produce robust and highly reproducible lot-to-lot consistency. Only top-performing clones are released for use by researchers. Each antibody is validated for high specificity and affinity across multiple applications, including its most commonly used application. ZooMAb® antibodies are reliably available and ready to ship when you need them.
Specificity
Clone 1K15 is a ZooMAb® recombinant rabbit monoclonal antibody that specifically detects Ras-related protein Rap-1A. It targets an epitope within 14 amino acids from the C-terminal region.
Immunogen
KLH-conjugated linear peptide corresponding to 14 amino acids from the C-terminal region of human Ras-related protein Rap-1A.
Application
Quality Control Testing
Evaluated by Western Blotting in HDLM-2 cell lysate.
Western Blotting Analysis (WB): A 1:10,000 dilution of this antibody detected RAP1A in HDLM-2 cell lysate.
Tested Applications
Flow Cytometry Analysis: 0.1 µg from a representative lot detected RAP1A in one million HDLM-2 cells.
Immunocytochemistry Analysis: A 1:100 dilution from a representative lot detected RAP1A in HDLM-2 cells.
Affinity Binding Assay: A representative lot of this antibody bound RAP1A peptide with at least one thousand-fold (1,000X) higher than with non-specific control peptide.
Note: Actual optimal working dilutions must be determined by end user as specimens, and experimental conditions may vary with the end user.
Target description
Ras-related protein Rap-1A (UniProt: P62834; also known as EC:3.6.5.2, C21KG, G-22K, GTP-binding protein smg p21A, Ras-related protein Krev-1, Rap1A) is encoded by the RAP1A (also known as KREV1) gene (Gene ID: 5906) in human. This gene encodes a member of the Ras family of small GTPases. The Ras superfamily is a large group of proteins that cycle between GDP and GTP-bound forms and interact with proteins depending on the nucleotide that is bound. Rap1 binds either GDP or GTP, and the change between the two states represents a molecular switch mechanism where the active GTP-bound state is ′on′ and the inactive GDP-bound state ′off′. Rap1A is a cell membrane and lipid anchor protein. Additionally, Rap-1A can also be found in the cytoplasm and associated with intracellular membranes, such as endosomes and the Golgi apparatus. It is a ubiquitously expressed protein that was first identified as a ras-tumor-suppressor gene in ras-transformed NIH/3T3 fibroblasts. High expression levels are observed in the brain, heart, lungs, and immune cells. The expression of Rap-1A can be regulated by various factors, including growth factors, cytokines, and cellular stress. It is synthesized with a short propeptide (aa 182-184) that is subsequently cleaved off to produce the mature, functional protein that has four GTP-binding sites. This protein is activated by several types of guanine nucleotide-exchange factors (GEFs) EPAC and EPAC2 in a cAMP-dependent manner and, inactivated by two groups of GTPase-activating proteins (GAPs). The activation status of the protein is therefore affected by the balance of intracellular levels of GEFs and GAPs. Rap1A counteracts the mitogenic function of Ras, at least partly because it can interact with Ras GAPs and RAF in a competitive manner. It is reported to induce morphological reversion of a cell line transformed by a Ras oncogene. Altered Rap-1A activity has been observed in various cancers, including melanoma, breast cancer, and colorectal cancer. Beyond cancer, Rap-1A is involved in cardiovascular diseases, where it plays a role in endothelial cell function and vascular integrity. This ZooMAb® recombinant monoclonal antibody, generated by our proprietary technology, offers significantly enhanced specificity, affinity, reproducibility, and stability over conventional monoclonals. (Ref.: Bos, JL., et al. (2001). Nat. Rev. Mol. Cell Biol. 2(5); 369-377).
Physical form
Purified recombinant rabbit monoclonal antibody IgG, lyophilized in PBS with 5% Trehalose, normal appearance a coarse or translucent resin. The PBS/trehalose components in the ZooMAb formulation can have the appearance of a semi-solid (bead like gel) after lyophilization. This is a normal phenomenon. Please follow the recommended reconstitution procedure in the data sheet to dissolve the semi-solid, bead-like, gel-appearing material. The resulting antibody solution is completely stable and functional as proven by full functional testing. Contains no biocide or preservatives, such as azide, or any animal by-products. Larger pack sizes provided as multiples of 25 µL.
Reconstitution
300 µg/mL after reconstitution at 25 µL per vial. Please refer to guidance on suggested starting dilutions and/or titers per application and sample type.
Storage and Stability
Recommend storage of lyophilized product at 2-8°C; Before reconstitution, micro-centrifuge vials briefly to spin down material to bottom of the vial; Reconstitute each vial by adding 25 µL of filtered lab grade water or PBS; Reconstituted antibodies can be stored at 2-8°C, or -20°C for long term storage. Avoid repeated freeze-thaws.
Legal Information
ZooMAb is a registered trademark of Merck KGaA, Darmstadt, Germany
Disclaimer
Unless otherwise stated in our catalog or other company documentation accompanying the product(s), our products are intended for research use only and are not to be used for any other purpose, which includes but is not limited to, unauthorized commercial uses, in vitro diagnostic uses, ex vivo or in vivo therapeutic uses or any type of consumption or application to humans or animals.